EUSA Pharma

Trans-Atlantic specialty pharmaceutical company focused on oncology and critical care

Trans-Atlantic specialty pharma company acquired by Jazz Pharma for $700 million in 2012

EUSA Pharma was a trans-Atlantic specialty pharma company founded by CEO Bryan Morton and his team in 2006 with a focus on Critical Care and Oncology. The company built a sales and marketing infrastructure in the US and Europe based around a portfolio of high value specialty products, including Erwinaze™, a new treatment for acute lymphoblastic leukemia. Erwinaze™ received FDA approval in 2011 and was launched successfully in the US in 2012.

  • Oxford, United Kingdom

  • Contact:
    Petri Vainio
  • IPO
  • Acquisition
  • Acquired by: Jazz Pharmaceuticals
  • Exit date: April 30, 2012
  • Logo

Related News

“EW Healthcare Partners is not so much an Investor as a Partner in building successful businesses as was my experience with EUSA.”

Bryan Morton

Chief Executive Officer, EUSA Pharma

Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.